Header Logo

Connection

Julie Schneider to Ethylene Glycols

This is a "connection" page, showing publications Julie Schneider has written about Ethylene Glycols.
Connection Strength

0.694
  1. Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of alzheimer dementia and detection of preclinical cortical amyloid. J Neuropathol Exp Neurol. 2014 Oct; 73(10):948-53.
    View in: PubMed
    Score: 0.123
  2. Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates. J Neuropathol Exp Neurol. 2014 Jan; 73(1):72-80.
    View in: PubMed
    Score: 0.117
  3. Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions. J Alzheimers Dis. 2014; 42(3):813-21.
    View in: PubMed
    Score: 0.117
  4. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-? plaques: a prospective cohort study. Lancet Neurol. 2012 Aug; 11(8):669-78.
    View in: PubMed
    Score: 0.105
  5. Correlation of amyloid PET ligand florbetapir F 18 binding with A? aggregation and neuritic plaque deposition in postmortem brain tissue. Alzheimer Dis Assoc Disord. 2012 Jan-Mar; 26(1):8-16.
    View in: PubMed
    Score: 0.101
  6. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011 Jan 19; 305(3):275-83.
    View in: PubMed
    Score: 0.095
  7. Genetic epistasis regulates amyloid deposition in resilient aging. Alzheimers Dement. 2017 Oct; 13(10):1107-1116.
    View in: PubMed
    Score: 0.036
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.